Creation of an in vitro model of GM1 gangliosidosis by CRISPR/Cas9 knocking‐out the GLB1 gene in SH‐SY5Y human neuronal cell line

• Published in: Cell biochemistry and function 2024-08, Vol.42 (6), p.e4102-n/a
• Main Authors: Hosseini, Kamran, Fallahi, Jafar, Aligholi, Hadi, Heidari, Zahra, Nadimi, Elham, Safari, Fatemeh, Sisakht, Mohsen, Atapour, Amir, Khajeh, Sahar, Tabei, Seyed Mohammad Bagher, Razban, Vahid
• Format: Article
• Language: English
• Subjects: beta-Galactosidase - genetics; beta-Galactosidase - metabolism; Cell lines; cell model; Cell proliferation; Cell size; Clonal deletion; Cloning; Cloning vectors; CRISPR; CRISPR-Cas Systems; CRISPR/Cas9; Data analysis; Dilution; Electroporation; Enzymatic activity; Enzyme activity; Enzymes; Error analysis; Error reduction; Exons; Flow cytometry; Galactosidase; Gangliosidosis; Gangliosidosis, GM1 - genetics; Gangliosidosis, GM1 - metabolism; Gene deletion; Gene expression; Gene Knockout Techniques; Gene sequencing; Genes; GLB1 gene; GM1 gangliosidosis; Humans; knock‐out; Lipids; Models, Biological; Nerves; Neurons - metabolism; Ribonucleic acid; RNA; SH‐SY5Y cell line; Staining; Substrates
• ISSN: 0263-6484; 1099-0844; 1099-0844
• DOI: 10.1002/cbf.4102

GM1 gangliosidosis is one type of hereditary error of metabolism that occurs due to the absence or reduction of β‐galactosidase enzyme content in the lysosome of cells, including neurons. In vitro, the use of neural cell lines could facilitate the study of this disease. By creating a cell model of GM1 gangliosidosis on the SH‐SY5Y human nerve cell line, it is possible to understand the main role of this enzyme in breaking down lipid substrate and other pathophysiologic phenomena this disease. To knock‐out the human GLB1 gene, guides targeting exons 14 and 16 of the GLB1 gene were designed using the CRISPOR and CHOP‐CHOP websites, and high‐efficiency guides were selected for cloning in the PX458 vector. After confirming the cloning, the vectors were transformed into DH5α bacteria and then the target vector was extracted and transfected into human nerve cells (SH‐SY5Y cell line) by electroporation. After 48 h, GFP+ cells were sorted using the FACS technique and homozygous (compound heterozygous) single cells were isolated using the serial dilution method and sequencing was done to confirm them. Finally, gap PCR tests, X‐gal and Periodic acid‐Schiff (PAS) staining, and qPCR were used to confirm the knock‐out of the human GLB1 gene. Additionally, RNA sequencing data analysis from existing data of the Gene Expression Omnibus (GEO) was used to find the correlation of GLB1 with other genes, and then the top correlated genes were tested for further evaluation of knock‐out effects. The nonviral introduction of two guides targeting exons 14 and 16 of the GLB1 gene into SH‐SY5Y cells led to the deletion of a large fragment with a size of 4.62 kb. In contrast to the non‐transfected cell, X‐gal staining resulted in no blue color in GLB1 gene knock‐out cells indicating the absence of β‐galactosidase enzyme activity in these cells. Real‐time PCR (qPCR) results confirmed the RNA‐Seq analysis outcomes on the GEO data set and following the GLB1 gene knock‐out, the expression of its downstream genes, NEU1 and CTSA, has been decreased. It has been also shown that the downregulation of GLB1‐NEU1‐CTSA complex gene was involved in suppressed proliferation and invasion ability of knock‐out cells. This study proved that using dual guide RNA can be used as a simple and efficient tool for targeting the GLB1 gene in nerve cells and the knockout SH‐SY5Y cells can be used as a model investigation of basic and therapeutic surveys for GM1 gangliosidosis disease. Significance statement Th